TrustRadius: an HG Insights company

What is Lympid?

Lympid is a European Tokenization-as-a-Service platform designed to help companies structure, issue, distribute, and manage tokenized investment products.


Core capabilities

Lympid combines financial product structuring, tokenization infrastructure, white-label technology, investor onboarding, KYC/AML workflows, subscription management, reporting, and lifecycle management within a single platform. It supports the creation of tokenized securities and investment products linked to assets such as real estate, private credit, funds, commodities, and other real-world assets.


Regulated distribution

Lympid is designed for issuers seeking to distribute investment products to eligible investors across European markets. Its infrastructure integrates regulated distribution capabilities with digital asset technology, helping issuers manage both the technical and financial-services requirements associated with launching tokenized products.


White-label infrastructure

Asset managers, real estate developers, financial institutions, and other issuers can use Lympid's white-label infrastructure to launch investment platforms under their own brand without developing the complete technology stack internally.


Key differentiator

Rather than focusing only on converting an asset into a blockchain token, Lympid addresses the broader investment-product lifecycle, including structuring, compliance, investor access, distribution, servicing, and optional secondary-market functionality. This makes the platform suitable for businesses looking to move from asset tokenization to the launch and distribution of complete digital investment products.

Categories & Use Cases

Screenshots

Product screenshot
Product screenshot
Product screenshot

1 / 3

Product Demos

Technical Details

Technical Details
Deployment TypesSaaS
Mobile ApplicationNo
Supported CountriesEEA
Supported LanguagesENG, PT, ES, FR, DE

FAQs

What are Lympid's top competitors?
Brickken, Securitize, and NYALA are common alternatives for Lympid.